STOCK TITAN

Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Simulations Plus to report Q4 and fiscal 2023 financial results on October 25, 2023
Positive
  • Simulations Plus will report its fourth quarter and fiscal 2023 financial results after market close on October 25, 2023.
Negative
  • None.

Conference call to be on Wednesday, October 25, 2023, at 5 p.m. EDT

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25, 2023.

Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the investor relations page of the Simulations Plus website at www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2022 ESG update.

Simulations Plus Investor Relations

Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com

Financial Profiles

Tamara Gonzalez

310-622-8234

slp@finprofiles.com

Source: Simulations Plus, Inc.

FAQ

When will Simulations Plus report its Q4 and fiscal 2023 financial results?

Simulations Plus will report its Q4 and fiscal 2023 financial results on October 25, 2023.

What time is the conference call to discuss the results?

The conference call to discuss the results will be at 5:00 p.m. Eastern Time on October 25, 2023.

How can I access the conference call?

You can access the conference call by registering for the live webcast on the Simulations Plus website or by dialing the provided phone numbers.

Will the webcast be available for replay?

Yes, the webcast will be available for replay approximately one hour following the call on the investor relations page of the Simulations Plus website.

Simulations Plus, Inc.

NASDAQ:SLP

SLP Rankings

SLP Latest News

SLP Stock Data

963.47M
16.19M
18.89%
78.83%
6.01%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
United States of America
LANCASTER

About SLP

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res